|
| Press Releases |
|
 |
|
| Thursday, May 2, 2024 |
|
|
Q&M Dental Enhances Digital Capabilities by Integrating Align Technology's Newest iTero Lumina(TM) Intraoral Scanner Across Dental Clinics in Singapore |
| Mainboard listed Q&M Dental Group (Singapore) Limited ("Q&M" or "the Company" and together with its subsidiaries, the "Group") is proud to announce its integration of Align Technology's ("Align") iTero Lumina(TM) Intraoral Scanner in Singapore. more info >> |
|
| Tuesday, April 23, 2024 |
|
|
EM2AI Revolutionising the Dental Industry: New AI Products Promise Transparent Treatment Plans for Patients |
| EM2AI Pte. Ltd., ("EM2AI" or the "Company") an Artificial Intelligence (AI) dental healthcare company based in Singapore today announced a groundbreaking development poised to reshape the landscape of dental care, with the launch of its pioneering dental AI product. more info >> |
|
| Friday, March 3, 2023 |
|
|
CATALIST-listed AOXIN Q&M reports lower revenue of RMB 140m for full year ended 31 December 2022 |
| Catalist listed Aoxin Q&M Dental Limited, announced on 1 March 2023, a 12.8% lower revenue of RMB139.7 million for full year ended 31 December 2022 (FY2022). The Group reported a net loss after tax excluding impairment loss on investment in our associate of RMB7.3 million for FY2022, primarily due to the number of shutdowns from China's zero-Covid policy that was in place all the way up until 8 January 2023. more info >> |
|
| Wednesday, February 23, 2022 |
|
|
CATALIST-listed AOXIN Q&M records 21% growth in revenue for full year ended 31 December 2021 |
| Catalist listed Aoxin Q&M Dental Limited ("Aoxin" or "the Group"), today announced a 20.8% increase in revenue to RMB160.2 million for full year ended 31 December 2021 ("FY2021"). more info >> |
|
| Monday, October 4, 2021 |
|
|
Aoxin Q & M acquires 49% stake in Acumen Diagnostics for S$29.4m |
| Aoxin Q & M Dental Group Ltd (SGX: 1D4.SI) ("Aoxin Q & M") and Q & M Dental Group (Singapore) Limited (SGX: QC7.SI) ("Q & M"), announced today that Aoxin Q & M will acquire 49% of Acumen Diagnostics Pte. Ltd. ("Acumen Diagnostics") for a consideration of S$29.4 million. Acumen Diagnostics has a preliminary valuation of S$60 million. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
GIC Invests US$100M in Ascletis Pharma (1672. HK): Anchoring Long-Term Capital in China's Core Innovative Drug Assets
Feb 6, 2026 17:45 HKT/SGT
|
|
|
COSMOPlat Introduces Full-Stack AI to Hong Kong for Trillion-Dollar Industrial Digitalization
Feb 6, 2026 17:34: JST
|
|
|
GIC Private Limited initiated a stake in Ascletis Pharma (01672) by 64,128,000 shares at a price of HKD 12.18 per share
Feb 6, 2026 17:01 HKT/SGT
|
|
|
歌禮製藥-B（01672）獲新加坡政府投資公司首次入股 涉資約1億美元
Feb 6, 2026 16:56 HKT/SGT
|
|
|
歌礼制药-B（01672）获新加坡政府投资公司首次入股 涉资约1亿美元
Feb 6, 2026 16:50 HKT/SGT
|
|
|
COSMOPlat Introduces Full-Stack AI to Hong Kong for Trillion-Dollar Industrial Digitalization
Feb 6, 2026 16:34 HKT/SGT
|
|
|
トヨタ、役員人事を発表
Feb 6, 2026 16:00: JST
|
|
|
Distinct Healthcare Successfully Listed on HKEX, Bolstered by Premium Customer Base and All-Star Cornerstone Investors
Feb 6, 2026 15:55 HKT/SGT
|
|
|
Muyuan Foods Makes Hong Kong Debut Today: Strong Cornerstone Investor Backing Fuels Rapid Earnings Growth, Embarking on New Journey of Internationalization
Feb 6, 2026 15:40 HKT/SGT
|
|
|
Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately to Severely Active Ulcerative Colitis
Feb 6, 2026 15:17: JST
|
|
|
牧原股份港股上市：全球生豬养殖龍頭 價值成長兼具
Feb 6, 2026 15:08 HKT/SGT
|
|
|
牧原股份港股上市：全球生猪养殖龙头 价值成长兼具
Feb 6, 2026 15:01 HKT/SGT
|
|
|
優異供應鏈賦能與國際化佈局雙輪驅動 綠茶開啟高質量成長新篇章
Feb 6, 2026 14:47 HKT/SGT
|
|
|
优异供应链赋能与国际化布局双轮驱动 绿茶开启高质量成长新篇章
Feb 6, 2026 14:33 HKT/SGT
|
|
|
Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately to Severely Active Ulcerative Colitis
Feb 6, 2026 14:17 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
